低剂量非那雄胺或度他雄胺治疗男性雄激素性脱发对前列腺特异性抗原浓度的影响
这项回顾性队列研究纳入1379例基线PSA<2.5 ng/ml、因雄激素性脱发接受低剂量非那雄胺(1.25 mg/日)或度他雄胺(0.5 mg/每3天)治疗的男性,评估PSA变化。总体PSA相对基线降低27.8%,79.3%患者PSA下降(平均40.8%),20.7%患者PSA稳定或升高(平均升高24.2%);仅基线PSA≥0.5 ng/ml者可见治疗相关下降。低剂量度他雄胺与非那雄胺降低PSA程度相似(31.1% vs 25.1%)。
要点
- 低剂量5α-还原酶抑制剂总体使PSA相对基线降低27.8%,79.3%患者PSA下降(平均40.8%)。
- 20.7%患者PSA稳定或升高(平均升高24.2%),低基线PSA与稳定/升高显著相关。
- 度他雄胺0.5 mg/每3天与非那雄胺1.25 mg/日降低PSA程度相似(31.1% vs 25.1%)。
核心结论
- 度他雄胺与非那雄胺降低PSA程度相似;该效应在治疗开始后不久即可观察到;基线PSA低的患者PSA可保持稳定甚至升高;这些发现仅限于基线PSA<2.5 ng/ml的男性。
研究设计与样本
- 回顾性队列研究,纳入2002至2012年因雄激素性脱发接受非那雄胺1.25 mg/日或度他雄胺0.5 mg/每3天治疗、且基线与至少一次后续PSA测量的1379例连续男性患者。
- 排除基线或处方后随访PSA超过2.5 ng/ml的患者,以排除前列腺癌可能性较高者;按年龄、基线PSA、药物类型和治疗时长分层。
主要发现
- 总体低剂量5α-还原酶抑制剂治疗使PSA相对基线降低27.8%。
- 1094例(79.3%)患者PSA下降,平均下降40.8%;其余285例(20.7%)PSA稳定或升高,平均升高24.2%。
- 进一步分析显示,仅基线PSA≥0.5 ng/ml的男性出现治疗相关PSA下降。
- 多因素logistic分析显示,低基线PSA与PSA稳定/升高显著相关。
- 低剂量度他雄胺与非那雄胺降低PSA程度相似(31.1% vs 25.1%);即使短期治疗(3至6个月)也观察到PSA明显下降26.0%。
局限性
- 这些发现仅限于基线PSA<2.5 ng/ml的男性。
- 原文为回顾性队列研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In this retrospective cohort study we assessed the effect on prostate specific antigen concentration of low dose finasteride or dutasteride treatment for male androgenetic alopecia in men with baseline serum prostate specific antigen less than 2.5 ng/ml. MATERIALS AND METHODS: The cohort consisted of 1,379 consecutive male patients who were treated for androgenetic alopecia with finasteride 1.25 mg daily or dutasteride 0.5 mg every 3 days in 2002 to 2012 and who underwent prostate specific antigen measurements at baseline and at least once thereafter. Patients in whom baseline or followup prostate specific antigen after prescription exceeded 2.5 ng/ml were excluded from study to rule out men with a higher likelihood of prostate cancer. Patients were stratified according to age, baseline prostate specific antigen, medication type and treatment duration. RESULTS: Overall low dose 5α-reductase inhibitor treatment reduced prostate specific antigen by 27.8% relative to baseline. Of the patients 1,094 (79.3%) showed prostate specific antigen decreases (average 40.8%). In the remaining 285 patients (20.7%) prostate specific antigen was stable or increased (average 24.2% increase). Closer analysis largely showed that only men with baseline prostate specific antigen 0.5 ng/ml or greater had a treatment related prostate specific antigen reduction. On multivariate logistic analysis low baseline prostate specific antigen was significantly associated with stable/increased prostate specific antigen. Low dose dutasteride and finasteride reduced prostate specific antigen to similar degrees (31.1% and 25.1%, respectively). A marked prostate specific antigen decrease of 26.0% was observed even after short-term treatment (3 to 6 months). CONCLUSIONS: Dutasteride and finasteride reduced prostate specific antigen to similar degrees. This effect was observed soon after commencing treatment. In patients with low baseline prostate specific antigen the levels could remain stable or even increase. These findings are limited to men with baseline prostate specific antigen less than 2.5 ng/ml.
引用
- Kang HW, Chae MH, Park SH, et al. Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia. J Urol. 2017. PMID: 28743526. doi:10.1016/j.juro.2017.07.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。